Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE INTRAVENOUS IMMUNOGLOBULIN IN (A) Administrative) AUSTRALIA, SECOND EDITION (B) Progressive (CRITERIA) (C) Programmed Condition Inflammatory myopathies: Inflammatory myopathies: polymyositis (PM), Inflammatory Myopathies have been split Name polymyositis (PM), dermatomyositis dermatomyositis (DM) and necrotising into 2 conditions - Inclusion Body Myositis (DM) and inclusion body myositis (IBM) autoimmune myopathy (NAM) as a separate condition from Polymyositis (PM) and Dermatomyositis (DM). This is because the criteria and evidence for IBM is different from PM/DM. SWG recommends that Necrotising Autoimmune Myopathy (NAM) that has been a subset of Polymyositis diagnostically but is now becoming recognised as a separate diagnostic entity as scientific knowledge improves. It was agreed that the capacity to use Ig should not be ceased and demand will not change by identifying these patients as a separate group. The number of patients is relatively small but should be tracked in data. SWG trial that NAM has a different level of evidence and agreed that it should be represented as a specific condition within the PM/DM Condition. (A)
Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM CRITERIA FOR THE CLINICAL USE OF INTRAVENOUS IMMUNOGLOBULIN IN AUSTRALIA, SECOND EDITION (CRITERIA) PROPOSED REVISIONS TO THE CRITERIA SWG RATIONALE FOR PROPOSED CHANGE (A) Administrative) (B) Progressive (C) Programmed Condition Name Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune myopathy (NAM) Inflammatory Myopathies have been split into 2 conditions - Inclusion Body Myositis as a separate condition from Polymyositis (PM) and Dermatomyositis (DM). This is because the criteria and evidence for IBM is different from PM/DM. SWG recommends that Necrotising Autoimmune Myopathy (NAM) that has been a subset of Polymyositis diagnostically but is now becoming recognised as a separate diagnostic entity as scientific knowledge improves. It was agreed that the capacity to use Ig should not be ceased and demand will not change by identifying these patients as a separate group. The number of patients is relatively small but should be tracked in data. SWG that NAM has a different level of evidence and agreed that it should be represented as a specific condition within the PM/DM Condition. (A) trial